{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:48:31Z","timestamp":1791388111196,"version":"4.3.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Optimal clinical application of the minimal clinically important difference (MCID) for the MMN-Rasch-built Overall Disability Scale\n                      <jats:sup>\u00a9<\/jats:sup>\n                      (MMN-RODS) scale is unknown.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively studied subjects with MMN from 2 UK\u00a0neuropathy centres. Raw and centile MMN-RODS scores were collected, at initial, two intermediate, and latest assessment, and distribution-based MCIDs determined at studied time-points. The sensitivities of raw, centile and individualised MCIDs, were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 32 consecutive subjects with MMN on individualised immunoglobulin dosing regimens. First intermediate, second intermediate, and latest assessments were performed at a median of 17.0, 54.1 and 74.6\u00a0months from onset, respectively. Progressive amelioration of mean raw MMN-RODS score occurred between initial and latest assessment. The distribution-based raw MMN-RODS MCID was of 3, 4 and 5, and the distribution-based centile MMN-RODS MCID was of 6, 7 and 7, at first intermediate, second intermediate and latest assessment, respectively. At first intermediate assessment, raw and individualised MCIDs were equally sensitive, and both more sensitive than centile MCID (McNemar\u2019s Test:\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Raw MCID, centile MCID and individualised MCID, all had equivalent sensitivity at the second intermediate and latest assessment. Neither initial MMN-RODS score, nor amplitude of treatment-induced changes in early disease stages, independently predicted total improvement amplitude or final outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MMN-RODS MCID cut-offs may require adaption to assessment timing. In earlier stages, raw\/individualised MCID may be more sensitive than centile MCID, whereas all three methods may subsequently be equivalent. Initial disability and early treatment response do not predict achievable total improvement amplitude nor final outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-13771-8","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T19:21:46Z","timestamp":1777231306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Raw, centile and individualised minimal clinically important differences for the MMN-Rasch-built Overall Disability Scale\u00a9 in the monitoring of multifocal motor neuropathy"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-8343","authenticated-orcid":false,"given":"Yusuf A.","family":"Rajabally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al-Areed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed A.","family":"Noushad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young G.","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinar","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,26]]},"reference":[{"issue":"2","key":"13771_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/jnnp-2019-321532","volume":"91","author":"WZ Yeh","year":"2020","unstructured":"Yeh WZ, Dyck PJ, van den Berg LH, Kiernan MC, Taylor BV (2020) Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry 91(2):140\u2013148","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"13771_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrneurol.2011.175","volume":"8","author":"L Vlam","year":"2011","unstructured":"Vlam L, van der Pol WL, Cats EA, Straver DC, Piepers S, Franssen H et al (2011) Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 8(1):48\u201358","journal-title":"Nat Rev Neurol"},{"issue":"Pt 5","key":"13771_CR3","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/brain\/awr318","volume":"135","author":"EK Vanhoutte","year":"2012","unstructured":"Vanhoutte EK, Faber CG, van Nes SI, Jacobs BC, van Doorn PA, van Koningsveld R et al (2012) Modifying the Medical Research Council grading system through Rasch analyses. Brain 135(Pt 5):1639\u20131649","journal-title":"Brain"},{"issue":"8","key":"13771_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70335","volume":"32","author":"YG Min","year":"2025","unstructured":"Min YG, Rajabally Z, Ju W, Lee J, Choi J, Mistry N et al (2025) Minimal clinically important difference for the Jamar hand grip dynamometer in CIDP: a Korea-UK study. Eur J Neurol 32(8):e70335","journal-title":"Eur J Neurol"},{"issue":"5","key":"13771_CR5","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/mus.28478","volume":"72","author":"YA Rajabally","year":"2025","unstructured":"Rajabally YA, Nazeer KK, Min YG (2025) Minimal clinically important differences in measuring treatment effects in CIDP: history, current use, limitations, and prospects. Muscle Nerve 72(5):1042\u20131051","journal-title":"Muscle Nerve"},{"issue":"3","key":"13771_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/jns.12141","volume":"20","author":"EK Vanhoutte","year":"2015","unstructured":"Vanhoutte EK, Faber CG, van Nes SI, Cats EA, Van der Pol WL, Gorson KC et al (2015) Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS(\u00a9) ). J Peripher Nerv Syst: JPNS 20(3):296\u2013305","journal-title":"J Peripher Nerv Syst: JPNS"},{"issue":"4","key":"13771_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jns.70079","volume":"30","author":"MA Noushad","year":"2025","unstructured":"Noushad MA, Al-Areed A, Iqbal R, Freiha J, Osman C, Rajabally YA (2025) Long-term functional outcomes in immunoglobulin-treated multifocal motor neuropathy evaluated through the MMN-Rasch-built overall disability scale. J Peripher Nerv Syst 30(4):e70079","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"13771_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1529-8027.2010.00290.x","volume":"15","author":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy","year":"2010","unstructured":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy (2010) Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2013first revision. J Peripher Nerv Syst: JPNS 15(4):295\u2013301","journal-title":"J Peripher Nerv Syst: JPNS"},{"issue":"3","key":"13771_CR9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/jns.12124","volume":"20","author":"MH Pruppers","year":"2015","unstructured":"Pruppers MH, Draak TH, Vanhoutte EK, Van der Pol WL, Gorson KC, L\u00e9ger JM et al (2015) Outcome measures in MMN revisited: further improvement needed. J Peripher Nerv Syst: JPNS 20(3):306\u2013318","journal-title":"J Peripher Nerv Syst: JPNS"},{"issue":"2","key":"13771_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/jns.70018","volume":"30","author":"YA Rajabally","year":"2025","unstructured":"Rajabally YA, Englezou C, Cluett G, Bellanti R, Rinaldi S, Chin MW et al (2025) Diagnosis and management of multifocal motor neuropathy in the United Kingdom: a multicentre survey. J Peripher Nerv Syst: JPNS 30(2):e70018","journal-title":"J Peripher Nerv Syst: JPNS"},{"issue":"12","key":"13771_CR11","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1007\/s00415-018-9071-9","volume":"265","author":"WN L\u00f6scher","year":"2018","unstructured":"L\u00f6scher WN, Oberreiter EM, Erdler M, Quasthoff S, Culea V, Berek K et al (2018) Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatment. J Neurol 265(12):2834\u20132840","journal-title":"J Neurol"},{"issue":"5","key":"13771_CR12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/CORR.0000000000002481","volume":"481","author":"CJ Hecht 2nd","year":"2023","unstructured":"Hecht CJ 2nd, Burkhart RJ, Karimi AH, Acu\u00f1a AJ, Kamath AF (2023) What is the association between clinically diagnosed psychiatric illness and total joint arthroplasty? A systematic review evaluating outcomes, healthcare use, and patient-reported outcome measures. Clin Orthop Relat Res 481(5):947\u2013964","journal-title":"Clin Orthop Relat Res"},{"issue":"6","key":"13771_CR13","doi-asserted-by":"publisher","first-page":"e1313","DOI":"10.1097\/SLA.0000000000005478","volume":"277","author":"MG Shamsunder","year":"2023","unstructured":"Shamsunder MG, Chu JJ, Polanco TO, Yin S, Muniz RC, James MC et al (2023) The impact of psychiatric diagnoses on patient-reported satisfaction and quality of life in postmastectomy breast reconstruction. Ann Surg 277(6):e1313\u2013e1323","journal-title":"Ann Surg"},{"issue":"8","key":"13771_CR14","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1111\/ene.14907","volume":"28","author":"D White","year":"2021","unstructured":"White D, Englezou C, Rajabally YA (2021) Patient perceptions of outcome measures in chronic inflammatory demyelinating polyneuropathy: a study of the Inflammatory Rasch-built Overall Disability Scale. Eur J Neurol 28(8):2596\u20132602","journal-title":"Eur J Neurol"},{"key":"13771_CR15","doi-asserted-by":"publisher","first-page":"173.e1","DOI":"10.1016\/j.jhsa.2025.03.022","volume":"51","author":"KR Miclau","year":"2025","unstructured":"Miclau KR, Kwong JW, Tapp E, Mulakaluri A, Shapiro LM (2025) Evaluating the Association Between Health Literacy and Patient-Reported Outcome Measures After Distal Radius Fracture. J Hand Surg Am. 51:173.e1-173.e10","journal-title":"J Hand Surg Am."},{"issue":"5","key":"13771_CR16","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.3928\/01477447-20240718-04","volume":"47","author":"EA Schultz","year":"2024","unstructured":"Schultz EA, Eppler SL, Gardner M, Hu SS, Chou L, Safran M et al (2024) Health numeracy is associated with a patient\u2019s ability to interpret patient-reported outcome measures data. Orthopedics 47(5):e255\u2013e260","journal-title":"Orthopedics"},{"issue":"5","key":"13771_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s43441-021-00298-5","volume":"55","author":"JC Cappelleri","year":"2021","unstructured":"Cappelleri JC, Chambers R (2021) Addressing bias in responder analysis of patient-reported outcomes. Ther Innov Regul Sci 55(5):989\u20131000","journal-title":"Ther Innov Regul Sci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13771-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:44:04Z","timestamp":1779446644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13771-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,26]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["13771"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13771-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,26]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YAR has received consultancy honoraria from Sanofi, Argenx, Janssen, LFB, Polyneuron, Grifols, Takeda, Dianthus, Vitaccess, has received educational sponsorships from LFB and CSL Behring and has obtained research grants from LFB. CO has received speaker\/consultancy honoraria from Takeda, Grifols and Terumo BCT. AA-A, RI, MAN and YGM have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"289"}}